Specialty & Oncology August 2020

Specialty & Oncology August 2020

Advances in the Management of Sickle Cell Disease

Three novel agents were recently approved to reduce the incidence of vaso-occlusive pain crises and/or anemia in sickle cell patients.

Guest Editorial: Assuming the Front Line of ADR Reporting

Pharmacists can contribute to the evolving understanding of the postmarketing surveillance that can lead to official FDA labeling updates and, perhaps, future medication-use recommendations.

Hemophilia Review

In recent years, a number of new drugs have been FDA-approved to treat this bleeding disorder, and recent trial data on gene therapy are promising.

Continuing Education

$6.97 Per CE Exam or $59 for 12 Lessons